Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Treated as a loss-making company. None of the usual models had enough data, so this uses Net asset value and Discounted cash flow instead.
ACCE opinionVoyager Therapeutics Inc. Common Stock (VYGR)
Fair value
Not available
ACCE price target
$2.10
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $1.74 at the close on 23 Oct 2026, 22:00 CEST.
Models: Net asset value and Discounted cash flow.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
28
out of 100
Analysts
100% buy
11 covering
P/E
0.0x
forward 8.4x
1-year return
-61.8%
Dividend yield
0.00%
Voyager Therapeutics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based capsids and delivery platforms for neurological disease, with its pipeline built around programs for Parkinson's and Alzheimer's. Its edge rests on proprietary capsid engineering meant to cross the blood-brain barrier, a platform that partners have licensed, which is where any near-term revenue has to come from. Revenue fell 39.1% over the latest reported period, and gross margin of -236.8% shows that collaboration income is not covering the cost of running the science. The market caps the company at roughly $127M, and at a forward P/E of 8.4 the stock is priced on expectations that partnership milestones or clinical data will arrive on schedule, not on current earnings. The score of 28/100 and absence from any index reflect that weakness, so this is a binary-catalyst name that warrants a deeper look only if the reader is prepared to underwrite trial and partnering outcomes.
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
severe
Deep operating losses
Operating margin is -833.9% and free cash flow is -$135.1M against a $126M market cap. Revenue fell 39.1% year over year, so the cash burn is not being covered by sales.
high
Revenue shrinking for years
Revenue has compounded at -25.1% over five years and dropped 39.1% in the latest year. Gross margin is -236.8%, so each sale currently loses money before overhead.
AI research notes
AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
The latest quarter beat expectations, with earnings per share of -0.40 against -0.55 expected, a 27.3% surprise.
Debt is modest against equity, with a debt to equity ratio of 0.19, leaving the balance sheet less leveraged than many peers.
Why it could disappoint
Revenue fell 39.1% over the past year and has declined by an average of 25.1% a year over five years.
Shares have been issued at a rate that dilutes holders, with the diluted share count up 1.8% last fiscal year.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 9, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where VYGR's valuation models land
Price
$1.74
Model fair valueConfidence: low
about $3.26
Model
Fair value
Upside
Net asset value
Discounted cash flow
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores